Renaissance Technologies LLC Buys 26,700 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)

Renaissance Technologies LLC lifted its stake in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) by 149.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 44,600 shares of the company's stock after purchasing an additional 26,700 shares during the quarter. Renaissance Technologies LLC owned 0.15% of Aerovate Therapeutics worth $118,000 as of its most recent SEC filing.Get Aerovate Therapeutics alerts:Other institutional investors have also added to or reduced their stakes in the company. ADAR1 Capital Management LLC boosted its position in shares of Aerovate Therapeutics by 720.7% in the fourth quarter. ADAR1 Capital Management LLC now owns 928,016 shares of the company's stock valued at $2,459,000 after acquiring an additional 814,941 shares during the period. Bank of Montreal Can grew its position in shares of Aerovate Therapeutics by 86.8% during the 4th quarter. Bank of Montreal Can now owns 59,097 shares of the company's stock valued at $157,000 after purchasing an additional 27,453 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Aerovate Therapeutics by 110.7% in the 4th quarter. Russell Investments Group Ltd. now owns 15,184 shares of the company's stock valued at $40,000 after acquiring an additional 7,977 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Aerovate Therapeutics by 1,021.1% during the 4th quarter. JPMorgan Chase & Co. now owns 67,165 shares of the company's stock valued at $178,000 after acquiring an additional 61,174 shares during the last quarter. Finally, Corient Private Wealth LLC bought a new position in shares of Aerovate Therapeutics in the fourth quarter worth approximately $98,000. Aerovate Therapeutics Price PerformanceShares of Aerovate Therapeutics stock opened at $10.09 on Thursday. Aerovate Therapeutics, Inc. has a 1 year low of $43.75 and a 1 year high of $884.98. The firm has a market cap of $292.46 million, a PE ratio of -3.37 and a beta of 0.95. The company has a 50 day simple moving average of $78.40 and a two-hundred day simple moving average of $85.32. Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) last released its earnings results on Friday, April 25th. The company reported ($3.15) EPS for the quarter, beating analysts' consensus estimates of ($10.50) by $7.35. As a group, research analysts anticipate that Aerovate Therapeutics, Inc. will post -2.64 earnings per share for the current year. Aerovate Therapeutics Announces DividendThe firm also recently disclosed a dividend, which was paid on Monday, April 28th. Stockholders of record on Friday, April 25th were issued a $84.00 dividend. The ex-dividend date was Tuesday, April 29th. Aerovate Therapeutics Company Profile (Free Report)Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.Featured ArticlesFive stocks we like better than Aerovate TherapeuticsThere Are Different Types of Stock To Invest InSurvey: America’s Most Inspirational Women Business Leaders [2025]Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?Disney Stock Jumps on Earnings—Is the Magic Sustainable?How to Invest in Biotech StocksWhat Oil, Value, and Growth Correlations Say About the MarketThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Aerovate Therapeutics Right Now?Before you consider Aerovate Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aerovate Therapeutics wasn't on the list.While Aerovate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here